VTYX
Ventyx Biosciences, Inc.
2.19
USD
This page is just a preview of the data found in TrendSpider’s full version
Ventyx Biosciences, Inc. stock is down -8.75% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 2 CALLs, 8 PUTs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 30 Oct 14:04 | 15 Dec, 2023 | 20.00 | 1035 | ||
| 30 Oct 16:40 | 15 Dec, 2023 | 20.00 | 1035 | ||
| 06 Nov 19:04 | 19 Jan, 2024 | 15.00 | 83 | ||
| 06 Nov 19:05 | 19 Jan, 2024 | 15.00 | 83 | ||
| 07 Nov 14:30 | 17 Nov, 2023 | 15.00 | 466 | ||
| 07 Nov 16:41 | 19 Jan, 2024 | 2.50 | 70 | ||
| 07 Nov 16:41 | 19 Jan, 2024 | 2.50 | 70 | ||
| 07 Nov 16:41 | 19 Jan, 2024 | 2.50 | 70 | ||
| 07 Nov 17:23 | 19 Jan, 2024 | 2.50 | 70 | ||
| 07 Nov 18:37 | 15 Dec, 2023 | 35.00 | 1031 |
Ventyx Biosciences, Inc. develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.
